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Abstract We and others have recently shown that angiotensin
II can activate the sodium chloride cotransporter (NCC)
through a WNK4–SPAK-dependent pathway. Because
WNK4 was previously shown to be a negative regulator of
NCC, it has been postulated that angiotensin II converts
WNK4 to a positive regulator. Here, we ask whether aldoste-
rone requires angiotensin II to activate NCC and if their effects
are additive. To do so, we infused vehicle or aldosterone in
adrenalectomized rats that also received the angiotensin recep-
tor blocker losartan. In the presence of losartan, aldosterone
was still capable of increasing total and phosphorylated NCC
twofold to threefold. The kinases WNK4 and SPAK also
increased with aldosterone and losartan. A dose-dependent
relationship between aldosterone and NCC, SPAK, and
WNK4 was identified, suggesting that these are aldosterone-
sensitive proteins. As more functional evidence of increased
NCC activity, we showed that rats receiving aldosterone and
losartan had a significantly greater natriuretic response to
hydrochlorothiazide than rats receiving losartan only. To study
whether angiotensin II could have an additive effect, rats
receiving aldosterone with losartan were compared with rats
receiving aldosterone only. Rats receiving aldosterone only
retained more sodium and had twofold to fourfold in-
crease in phosphorylated NCC. Together, our results
demonstrate that aldosterone does not require angioten-
sin II to activate NCC and that WNK4 appears to act as
a positive regulator in this pathway. The additive effect
of angiotensin II may favor electroneutral sodium reab-
sorption during hypovolemia and may contribute to
hypertension in diseases with an activated renin–angiotensin–
aldosterone system.
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Introduction
Angiotensin II and aldosterone are the chief hormones of the
renin–angiotensin–aldosterone system. In the last two deca-
des, aldosterone has been recognized as the primary hor-
mone regulating sodium transport along the distal nephron
[13, 16, 44]. Aldosterone exerts its effects on three parts of
the distal nephron, including the distal convoluted tubule
(DCT), connecting tubule (CNT), and cortical collecting
duct (CCD). In fact, this nephron segment is often referred
to as the “aldosterone-sensitive distal nephron (ASDN)”
[21, 39]. Via the mineralocorticoid receptor, aldosterone
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activates the two main sodium transporters in the ASDN: the
thiazide-sensitive sodium chloride cotransporter (NCC) lo-
cated in the “early” and “late” DCT [1] and the epithelial
sodium channel (ENaC) located in the “late” DCT, CNT,
and CCD [16]. Conversely, angiotensin II has traditionally
been considered to act primarily in the proximal tubule,
where it stimulates both the trafficking and phosphorylation
of the sodium hydrogen exchanger type 3 [34]. The last few
years, however, an emerging set of data has indicated that
angiotensin II can also activate NCC [15, 35, 36, 42] and, to
a lesser extent, ENaC [29]. These new insights have raised
the question as to the respective roles of angiotensin II and
aldosterone in the distal nephron and whether their effects
are mutually dependent. This question is of both physiolog-
ical and clinical relevance because aldosterone performs two
completely different functions during hypovolemia (when
angiotensin II is also increased) and hyperkalemia (when
angiotensin II is not increased). This has been coined the
“aldosterone paradox” [7, 9, 19, 43]. Of further interest is
the recent discovery of a kinase network that can favor the
sodium-retaining or potassium-secreting function of aldo-
sterone by selectively activating ion channels. This kinase
network consists of the Ste20-related kinase SPAK and
several members of the WNK (With No K0 lysine) kinase
family [18, 19, 39]. Recently, we conducted a study address-
ing the independent role of angiotensin II in the distal
nephron [42]. In adrenalectomized rats, we showed that
angiotensin II induced phosphorylation of NCC in the ab-
sence of aldosterone. These effects were mediated by SPAK,
which is capable of phosphorylating NCC [32]. Similarly, in
oocytes and cells, San-Cristobal and colleagues showed that
angiotensin II induced phosphorylation of NCC through
WNK4 and SPAK [35]. Although WNK4 was previously
shown to be a negative regulator of NCC [49], these authors
proposed that angiotensin II may convert WNK4 to becom-
ing a positive regulator of NCC [35]. Together, these recent
data raise the question whether aldosterone requires angio-
tensin II to activate NCC and whether the effects of aldo-
sterone and angiotensin II are additive. To address this,
adrenalectomized rats were infused with vehicle, normal
aldosterone, or high aldosterone in addition to the angioten-
sin II receptor blocker losartan.
Materials and methods
Animal studies
The animal protocol was approved by the Animal Care
Committee of the Erasmus Medical Center (EUR 127-08-
02). Three studies were performed in rats (all Sprague-
Dawley, 15 weeks old, average weight 370 g; Charles River,
Sulzfeld, Germany) (Supplemental Table 1). In the first
study, all rats were adrenalectomized (via bilateral lumbo-
dorsal incision) and were then randomized to receive no,
normal (50 μg/kg/day), or high aldosterone (100 μg/kg/
day). All rats also received losartan (10 mg/kg/day) [3, 25,
44]; this dose has been shown to inhibit 90 % of the
angiotensin receptor type 1 receptors [53]. Blood pressure
was measured every morning in conscious rats using a tail-cuff
system after a 7-day acclimatization period (Kent Scientific
Corporation, Torrington, CN, USA). In the second study, the
sensitivity to hydrochlorothiazide or amiloride was tested, as
described previously [14, 33]. Briefly, rats were adrenalecto-
mized and randomized into six groups. All rats received los-
artan (10 mg/kg/day). The first three groups also received
aldosterone (100 μg/kg/day) for 4 days after which hydrochlo-
rothiazide (25 mg/kg), amiloride (2 mg/kg), or vehicle was
injected intraperitoneally. The other three groups served as
controls and received the same diuretics or vehicle, but no
aldosterone. The diuretics were injected on the day of maxi-
mal sodium retention (day 4) and a timed urine was collected
5 h before and after these injections. Diuretic sensitivity was
defined as the urine sodium to creatinine ratio. In the third
study, the potentially additive effects of angiotensin II
and aldosterone were tested. For this, samples from the
first study and samples from our previously conducted
study [42] were used. Four adrenalectomized rats receiving
aldosterone (50 μg/kg/day) were compared to three adre-
nalectomized rats receiving aldosterone (50 μg/kg/day)
and losartan (10 mg/kg/day). In all studies, animals
were placed in metabolic cages after adrenalectomy and
insertion of minipumps (Alzet, Cupertino, CA, USA).
Throughout the study period, they were provided with normal
rat chow and drinking fluid (0.9 % NaCl) ad libitum; normal
saline was selected to compensate for natriuresis after adre-
nalectomy. All rats also received dexamethasone as glucocor-
ticoid replacement (12 μg/kg/day) [38].
Tissue preparation and plasma and urine measurements
Plasma renin activity and plasma aldosterone were mea-
sured as described previously [42]. Urine sodium and creat-
inine were determined with an automatic analyzer (Modular
IPPE, Roche Diagnostics, Almere, The Netherlands). The
right kidney was used for immunoblotting and was placed in
an isolation buffer (10 mM triethanolamine, 250 mM su-
crose, and protease inhibitors [Complete™, Roche Bio-
chemicals, Indianapolis, IN, USA]) and homogenized. The
whole kidney homogenate was subjected to differential cen-
trifugation, as described previously [5]. Sixty microliters of
both fractions was used for quantitative protein assay
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(Pierce, Thermo Scientific, Rockford, IL, USA) and the
remaining samples were stored in 6× Laemmli at −80 °C
for immunoblotting.
Immunoblotting
Immunoblotting was performed as described previously
[13]. For the first study, samples of all rats were immuno-
blotted simultaneously using two gels in one transfer appa-
ratus including an internal standard. Antibodies against the
following transport proteins were obtained: the α-, β-, and
γ-subunits of ENaC (all 1:1,000), aquaporin-2 (AQP2)
(1:1,000; all StressMarq, Victoria, BC, Canada), NCC and
actin (1:500 and 1:100,000; Millipore, Temecula, CA,
USA), SPAK (Cell Signaling, Boston MA, USA), and
WNK4 (Division of Signal Transduction Therapy, Univer-
sity of Dundee, Dundee, Scotland, UK). Antibodies against
pNCC (1:500) were generated by one of the investigators
(RAF). Specificity of the SPAK antibody was confirmed
using kidney tissue from SPAK−/− mice (data not shown).
Immunohistochemistry
The left kidney was used for immunohistochemistry. The
midregion was sectioned into 2- to 3-mm transverse sections
and immersion-fixed for an additional 1 h, followed by three
times 10-min washes with 0.1 mol/l cacodylate buffer (pH
7.4). The tissue was dehydrated in graded alcohol, incubated
overnight in xylene, and embedded in paraffin, and 2-μm
sections were cut on a rotary microtome (Leica Microsys-
tems, Herlev, Denmark). Immunolabeling was performed as
described previously [12, 28]. Labeling was detected using a
horseradish peroxidase-conjugated secondary antibody
(Dako P448, goat anti-rabbit IgG, Glostrup, Denmark) and
visualized with 0.05 % 3,3′-diaminobenzidine tetrachloride
(Kemen Tek, Copenhagen, Denmark). Light microscopy
was carried out with a Leica DMRE (Leica Microsystems,
Herlev, Denmark).
Quantitative PCR
Renal cortex was placed in RNALater (Qiagen, Valencia,
CA, USA) and isolated using RNeasy® Mini Kit (Qiagen,
Valencia, CA, USA). Five micrograms of RNAwas used for
first-strand cDNA (SuperScript™ II reverse transcriptase,
Invitrogen, Carlsbad, CA, USA). The reaction was inacti-
vated by raising the temperature to 70 °C for 5 min, fol-
lowed by the addition of RNAse and 15 min incubation at
37 °C. The amplifications were performed using the SYBR
Green PCR Master Mix (Applied Biosystem, Foster City,
CA, USA). The reactions were set for 40 cycles at 60 °C in a
Step One Plus System (Applied Biosystem, Foster City, CA,
USA). Relative standard curve method was used for calcu-
lation. Standard curves enabled target gene quantification
and normalization to an endogenous control (hypoxanthine–
guanine phosphoribosyltransferase, Real Time Primers
LLC, Elkins Park, PA, USA). All PCR products were
checked by sequencing.
Fig. 1 Physiological effects of
aldosterone with losartan.
Adrenalectomized rats received
no aldosterone (Control, n05),
normal aldosterone (Aldo, n0
5), or high aldosterone (Aldo-H,
n05) with losartan for 8 days.
At the end of the experiment,
the plasma renin activity and
the plasma aldosterone
concentration were measured
(a, b). During the experiment,
arterial blood pressure and
24-h urinary sodium excretions
were measured (c, d).
By analysis of variance and
post hoc test. MAP mean arte-
rial pressure, NS not significant;
*P<0.01
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Statistics
All data are expressed as the means and standard error of the
mean. Group comparisons were made by using a Student’s t
test or analysis of variance with a post hoc test, as appropriate.
Blood pressure data were analyzed using two-way analysis of
variance. Correlations were calculated using Pearson’s rho.
Because of the wide range, the natural logarithm of the plasma
aldosterone concentration was used for these calculations. P≤
0.05 was considered statistically significant.
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Fig. 2 Effects of aldosterone with losartan on renal sodium trans-
porters. Immunoblots showing the effects of aldosterone with losartan
on the NCC (a), the ENaC and the water channel AQP2 (b). In
addition, the effects of aldosterone with losartan on two regulatory
kinases, WNK4 and SPAK, are shown (c). Whole kidney homogenates
were differentially centrifuged to obtain plasma membrane fractions
(used for all transport proteins) and intracellular fractions (used for the
regulatory kinases). Densitometry was normalized for actin. *P<0.05
by analysis of variance and post hoc test
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Results
Animal model to study the effects of aldosterone
independent of angiotensin II
Rats were adrenalectomized and then received the an-
giotensin receptor blocker losartan in addition to vehi-
cle, normal aldosterone, or high aldosterone. This dose
of losartan has been shown to inhibit 90 % of angio-
tensin type 1 receptors [53]. Plasma renin activity was
significantly higher in the control group (Fig. 1a). The
plasma aldosterone concentrations (Fig. 1b) confirmed
that both the adrenalectomy and the delivery of two
doses of exogenous aldosterone were successful. Blood
pressure was similar in all three groups throughout the
experiment (Fig. 1c). The aldosterone-infused groups
retained more sodium, whose maximal effect was
reached on the fourth day (Fig. 1d). At the end of the
experiment, plasma creatinine and urine osmolarity were
similar in all three groups (data not shown). Together,
these data demonstrate that we successfully established
an in vivo model to investigate the sodium-retaining
effect of aldosterone independent of angiotensin II and
independent of changes in blood pressure and glomeru-
lar filtration rate.
Independent effects of aldosterone on transporters
and regulatory proteins
Aldosterone infusion increased the abundance and phos-
phorylation of NCC twofold to threefold (Fig. 2a). A further
increase in protein expression with the higher aldosterone
dose was observed only for total NCC, but not for phos-
phorylation at threonine 53 and 58. Both doses of aldoste-
rone also increased the α- and γ-subunits, but not the β-
subunit of ENaC (Fig. 2b). The higher dose of aldosterone
increased α-ENaC abundance from approximately twofold
to fourfold, whereas the increase in γ-ENaC abundance
was similar with the normal and high aldosterone doses.
Both the 70- and 85-kD subunits of γ-ENaC increased
significantly with aldosterone. The water channel AQP2
also increased approximately threefold with both doses
of aldosterone (Fig. 2b). The abundances of the regula-
tory kinases WNK4 and SPAK increased with both
aldosterone doses, whereas the phosphorylated form of
SPAK increased significantly only with the normal al-
dosterone dose (Fig. 2c). Immunohistochemistry confirmed the
increase of phosphorylated NCC at threonine 53 and of AQP2
(Fig. 3). It was of interest that aldosterone increased the total
expression of AQP2 mainly by inducing basolateral expres-
sion. As well as protein expression data, we also studied the
Fig. 3 Immunohistochemical analysis of the NCC and AQP2. Immu-
nohistochemistry for NCC phosphorylated at threonine 53 (pNCC) in
the DCT (a) and the water channel AQP2 in the collecting duct (b). a
and b show representative images of kidney sections from adrenalec-
tomized rats treated with losartan only (left, ADX+Losartan), aldoste-
rone and losartan (middle, ADX + Losartan + Aldo), and a high dose of
aldosterone and losartan (right, ADX + Losartan + Aldo-H). In a and
b, the more intense staining in the two experimental groups compared
to the control group is clearly visible. In b, the more intense staining
was attributed mainly to the induction of basolateral expression of
AQP2
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effects of aldosterone on the mRNA abundance of transporters
and kinases. Although the mRNA abundance of α-ENaC
increased significantly with aldosterone (Fig. 4), no significant
changes in mRNA abundance were identified for NCC, SPAK,
or WNKs. This could not be attributed to the administration of
losartan because SPAK mRNA also remained unchanged with
aldosterone alone (data not shown).
Aldosterone increased the sensitivity to hydrochlorothiazide
and amiloride
A diuretic sensitivity study was conducted in a separate
experiment as a measure of the activity of NCC and ENaC
during treatment with aldosterone and losartan (Fig. 5).
Diuretic sensitivity was defined as the difference in urine
sodium to creatinine or urine potassium to creatinine ratio
before and after the administration of vehicle or diuretic. As
expected, diuretic treatment resulted in significantly higher
urine sodium to creatinine ratio in the groups with and
without aldosterone. Hydrochlorothiazide increased kaliure-
sis, whereas amiloride reduced kaliuresis. More importantly,
Fig. 4 Effects of losartan with aldosterone on mRNA levels of NCC,
α-ENaC, SPAK, and WNKs. The transcript abundances of SPAK,
NCC, WNK4, L-WNK1, and KS-WNK1 are shown in adrenalecto-
mized rats treated with losartan and no, normal, or high aldosterone.
There were no significant changes among groups (using analysis of
variance). As positive control, the transcript abundance of α-ENaC is
shown for adrenalectomized rats that received no or normal aldoste-
rone but no losartan (upper right). Aldosterone led to a significant
increase in α-ENaC mRNA. All data represent the average value of
five rats. In these experiments, results were normalized for the abun-
dance of the housekeeping protein hypoxanthine–guanine phosphor-
ibosyltransferase. As a control, specificity of the amplified products
was determined using melting curve analysis and by product sequenc-
ing. NS not significant; *P=0.05
Fig. 5 Diuretic sensitivity test. Results of a diuretic sensitivity test
expressed as the change in urine sodium to creatinine ratio (ΔUNa/
UCreat) or urine potassium to creatinine ratio (ΔUK/UCreat) before and
after the injection of vehicle or diuretic. Each symbol represents one
rat. The three groups in the left of the figure (black symbols) represent
adrenalectomized rats (ADX) that received losartan (LOS). After 4 days,
one of these groups was injected with vehicle (VEH, black inverted
triangle), whereas the other two groups received a diuretic, including
hydrochlorothiazide (HCTZ, black diamond) or amiloride (AML, black
circle). The three groups in the right of the figure (open symbols)
represent adrenalectomized rats that received aldosterone (ALDO) with
losartan. After 4 days, one of these groups also received vehicle (white
inverted triangle), whereas the other two groups received a diuretic,
including HCTZ (white diamond) or AML (white circle). In all groups,
diuretic treatment resulted in a significantly higher UNa/UCreat than
vehicle (*P<0.01 using analysis of variance). UK/UCreat increased
significantly with HCTZ (except in the group without aldosterone)
and decreased significantly with AML. The natriuretic and kaliuretic
response to HCTZ in rats that also received aldosterone was signifi-
cantly greater (P00.05 and P00.02, respectively). AML also caused a
greater natriuretic response to HCTZ in rats receiving aldosterone (P0
0.04)
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however, the increase in urine sodium to creatinine to hy-
drochlorothiazide or amiloride was significantly greater in
those animals that also received aldosterone, suggesting
increased activity of NCC and ENaC. Similarly, the increase
in urine potassium to creatinine was also significantly greater
in the animals receiving hydrochlorothiazide and aldosterone.
Additive effect of angiotensin II and aldosterone
In the final experiment, we examined whether aldosterone in
combination with angiotensin II had an additive effect on
renal sodium excretion and the abundance of NCC and
ENaC. Seven rats were selected on the basis of similar plasma
aldosterone concentrations (Fig. 6). Because only three of
these rats also received losartan, this comparison allowed a
selective analysis of an angiotensin II effect. Urinary sodium
excretion was higher in adrenalectomized rats that received
aldosterone and losartan, suggesting that inhibition of angio-
tensin II action resulted in greater natriuresis. Interestingly,
phosphorylation of NCC was markedly reduced in the pres-
ence of losartan, both at threonine 53 and 58. Conversely,
there was a trend towards a higher total NCC abundance with
losartan, but this did not reach significance. Although a trend
was observed for lower SPAK abundance with losartan, this
was not statistically significant. Finally, the abundance of α-
ENaC remained unchanged.
Discussion
In addition to the classical role of aldosterone, there is an
increasing body of evidence to suggest that angiotensin II
also plays an important role in distal nephron sodium trans-
port [15, 35, 36, 42]. Since both hormones are usually
present together, it has been difficult to untangle their inde-
pendent and potentially additive roles in distal nephron
sodium transport. Here, we addressed this question by using
an in vivo model of adrenalectomy and aldosterone with or
without losartan. In the presence of losartan, aldosterone
still caused renal sodium retention (Fig. 1), which was
associated with increased expression of the distal sodium
transporters NCC, pNCC, α-ENaC, and γ-ENaC (Figs. 2
and 3). Although two fixed doses of aldosterone were used,
a range of plasma aldosterone concentrations were found.
As a more functional measure of NCC and ENaC activity, we
also showed that the natriuretic response to hydrochlorothia-
zide and amiloride was greater with aldosterone and losartan
than with losartan alone (Fig. 5). This suggests that increased
renal sodium retention with aldosterone and losartan was, at
least in part, due to increased NCC and ENaC activity [33].
Next, we focused on the NCC regulatory proteins WNK4
and SPAK, the abundance of which increased with aldoste-
rone and losartan (Fig. 2). Although SPAK has been clearly
established as a kinase capable of phosphorylating NCC
[22, 30], the role of WNK4 in the regulation of NCC is less
clear (reviewed in [18]). Several studies have demonstrated
that WNK4 can sometimes act as a negative regulator of
NCC by diverting post-Golgi NCC to lysosomal degrada-
tion [40, 48–50]. However, WNK4 hypomorphic mice have
reduced phosphorylation of NCC [27]. Similarly, WNK4
appears to mediate the phosphorylation of NCC during
treatment with angiotensin II [35], insulin [37], cyclosporine
[20], and tacrolimus [10]. Thus, the increase in both WNK4
and SPAK may have been related to their involvement
in the phosphorylation of NCC, although more function-
al data are required to confirm this impression. The
SPAK-mediated phosphorylation of NCC also suggests
that transporter activity is regulated mainly by posttran-
scriptional mechanisms. This was further supported by
the absence of changes in the mRNA abundance of
either SPAK or NCC (Fig. 4). It is not unusual to see changes
in protein expression without changes in mRNA levels. For
example, in previous studies, the increase in NCC protein with
aldosterone infusion [17] and the decrease in NCC protein
during aldosterone escape [45] were not associated with
corresponding changes in mRNA. While, like us, O’Reilly
and colleagues did not detect differences in mRNA ex-
pression of long WNK1 (L-WNK1) or WNK4 in adrenal-
ectomized mice treated with aldosterone for 6 days [26],
they did observe an increase in kidney-specific WNK1
(KS-WNK1), while we observed a trend towards increased
KS-WNK1 (Fig. 4).
Although SPAK, pNCC, NCC, and α-ENaC have all
previously been shown to be aldosterone-sensitive [2, 13,
16, 42], this is the first in vivo model to demonstrate that
aldosterone does not require angiotensin II for the upregu-
lation of these proteins. Besides angiotensin II, vasopressin
is of interest because it was recently shown to be capable of
phosphorylating NCC through SPAK [23, 28]. Although we
did not measure plasma vasopressin levels, the increase in
AQP2 expression we observed (Figs. 2 and 3) might either
have been indirect (through vasopressin) or direct (through
aldosterone). Proof of the latter was provided by experi-
ments in mpkCCDc14 cells, in which long-term incubation
with aldosterone increased AQP2 protein abundance by
increasing AQP2 mRNA translation [8]. As shown before
[4], the increase in AQP2 was due mainly to increased
basolateral expression of AQP2 (Fig. 3). It appears unlikely
that the AQP2 translocation contributes to water movement
because urine osmolality was unaffected and because AQP3
and AQP4 are also constitutively expressed in the basolat-
eral plasma membrane [24]. Interestingly, high sodium in-
take by itself has also been shown to upregulate ENaC and
AQP2 through an effect on collectrin, a homologue of
angiotensin-converting enzyme 2 that is expressed in the
apical membrane of the collecting duct [51].
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Our final question was whether aldosterone and angio-
tensin II could have an additive effect on sodium transport in
the distal nephron. To address this, we selected adrenalec-
tomized and aldosterone-infused rats on the basis of similar
plasma aldosterone concentrations (Fig. 6). Indeed, urinary
sodium excretion increased with the addition of losartan to
aldosterone-infused animals, suggesting a role of
angiotensin II in renal sodium retention (Fig. 6). Immuno-
blot analysis suggested that phosphorylated NCC but not
ENaC was involved in the additive effect of angiotensin II
because aldosterone with losartan reduced the phosphoryla-
tion of NCC at threonine 53 and 58 (Fig. 6). This adds to
recent work in which we show that angiotensin II induces
phosphorylation of NCC independently of aldosterone [42].
NCC  
pNCC Thr 53  
α-ENaC  
pNCC Thr 58  
~ 160 kDa
~ 160 kDa
~ 160 kDa
~ 85 kDa
Aldosterone
Losartan
+ +
_ +
Aldosterone
Losartan
+ +
_ +
Aldosterone
Losartan
+ +
_
+
Aldosterone
Losartan
+ +
_
+
SPAK  ~ 60 kDa
Aldosterone
Losartan
+ +
_ +
a
c
bFig. 6 Additive effects ofangiotensin II and aldosterone.
a shows that seven
adrenalectomized rats with
similar plasma aldosterone
concentrations were selected,
three of which also received
losartan. b shows that the
addition of losartan resulted in a
higher urinary sodium
excretion. c shows that the
addition of losartan reduced the
phosphorylation of NCC, while
there were no significant effects
on total NCC, SPAK, and α-
ENaC abundances. Densitome-
try was normalized for actin.
*P<0.05 by unpaired Student’s
t tests. ADX adrenalectomy,
Aldo aldosterone, NS not
significant
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The observation that angiotensin II selectively increases
pNCC but not ENaC is likely to be of physiological impor-
tance, as it could help explain the “aldosterone paradox” [7,
9, 19, 43]. During hypovolemia, plasma levels of angioten-
sin II and aldosterone are elevated. On the basis of our data,
this would favor sodium reabsorption by the DCT, limiting
the flow and delivery to the CNT and CCD and, therefore,
limiting potassium secretion [11]. Conversely, during hyper-
kalemia, when only aldosterone is elevated, sodium reab-
sorption by the CNT and CCD is more pronounced,
stimulating potassium secretion. According to this model,
angiotensin II could function as the “switch” between fa-
voring electroneutral sodium reabsorption by the DCT and
favoring electrogenic sodium reabsorption by the CNT and
CCD [9, 46]. This model is further supported by the inter-
esting recent finding that angiotensin II inhibits the renal
outer medullary potassium channel (ROMK) [52]. However,
the demonstration that a high potassium diet increased al-
dosterone but decreased NCC [6] suggests that other mech-
anisms are also involved. For example, a high potassium
diet has been shown to increase the KS-WNK1/WNK1 ratio
and the abundance of WNK4, which could inhibit NCC and
activate ENaC and ROMK [9, 26].
A number of limitations of this study should be men-
tioned. First, the number of animals in some of the studies
was small. Second, the results of our analysis on the additive
effects of angiotensin II should be considered preliminary
because samples from studies conducted at different times
were compared. These results should, therefore, be con-
firmed in a separate study using a direct comparison (infu-
sion of angiotensin II instead of losartan). Third, although
not measured, the supplementation of aldosterone may have
decreased plasma angiotensin II levels. Although losartan
inhibits the angiotensin II type 1 receptor, it leaves the
angiotensin II type 2 receptor unaffected. Therefore, in the
control group, higher plasma levels of angiotensin II may
have had effects through the angiotensin II type 2 receptor.
In this study, we focused on sodium transport by the
aldosterone-sensitive distal nephron. Although this part of
the kidney reabsorbs only 10–15 % of the filtered load of
sodium chloride, altered function of this kidney segment can
profoundly affect total body sodium and blood pressure
[31]. This is illustrated by the fact that activating mutations
of NCC and ENaC lead to renal sodium retention and
hypertension [41, 47]. Clinically, the renin–angiotensin–aldo-
sterone system is activated in many disease states, including
several forms of hypertension, heart failure, liver cirrhosis,
and nephrotic syndrome. Pharmacological inhibition of the
renin–angiotensin–aldosterone system is the cornerstone of
the treatment of these disorders. Unraveling the separate
effects of angiotensin II and aldosterone is important when
selecting appropriate pharmacological intervention for these
diseases with angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, or mineralocorticoid receptor
blockers.
In summary, by using adrenalectomy, aldosterone, and
losartan in rats, we have shown that aldosterone does not
require angiotensin II to activate NCC through a WNK4–
SPAK-dependent pathway. However, angiotensin II and al-
dosterone do appear to have additive effects on NCC.
This explains a specialized system for the hormonal
control of renal salt excretion that is relevant to health
and disease.
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